罕见病药物的可及性：为原发性纤毛运动障碍疾呼
Access to medicines for rare diseases: beating the drum for primary ciliary dyskinesia.
作者信息
Crowley Suzanne, Azevedo Inês, Boon Mieke, Bush Andrew, Eber Ernst, Haarman Eric, Karadag Bulent, Kötz Karsten, Leigh Margaret, Moreno-Galdó Antonio, Mussaffi Huda, Nielsen Kim G, Omran Heymut, Papon Jean-François, Pohunek Petr, Priftis Kostas, Rindlisbacher Bernhard, Santamaria Francesca, Valiulis Arunas, Witt Michal, Yiallouros Panayiotis, Zivkovic Zorica, Kuehni Claudia E, Lucas Jane S
机构信息
Paediatric Dept for Lung and Allergic diseases, Oslo University Hospital, Oslo, Norway.
Centro Materno-Pediátrico, Centro Hospitalar Universitário de S. João, Porto, Portugal.
出版信息
ERJ Open Res. 2020 Sep 14;6(3). doi: 10.1183/23120541.00377-2020. eCollection 2020 Jul.
相似文献
1
Access to medicines for rare diseases: beating the drum for primary ciliary dyskinesia.罕见病药物的可及性：为原发性纤毛运动障碍疾呼
ERJ Open Res. 2020 Sep 14;6(3). doi: 10.1183/23120541.00377-2020. eCollection 2020 Jul.
2
Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis.鼻腔一氧化氮测量及改良PICADAR评分在成人支气管扩张症患者原发性纤毛运动障碍筛查中的应用
Pneumologie. 2017 Aug;71(8):543-548. doi: 10.1055/s-0043-111909. Epub 2017 Aug 7.
3
4
Primary ciliary dyskinesia in six patients with bronchiectasis.6例支气管扩张患者的原发性纤毛运动障碍
Pneumonol Alergol Pol. 2016;84(2):109-15. doi: 10.5603/PiAP.2016.0009.
5
Long-term outcome of Tunisian children with primary ciliary dyskinesia confirmed by transmission electron microscopy.经透射电子显微镜证实的突尼斯原发性纤毛运动障碍儿童的长期预后。
Afr Health Sci. 2016 Dec;16(4):954-961. doi: 10.4314/ahs.v16i4.11.
6
Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers.不同欧洲中心治疗原发性纤毛运动障碍中铜绿假单胞菌根除策略的差异。
Chron Respir Dis. 2019 Jan-Dec;16:1479972318787919. doi: 10.1177/1479972318787919. Epub 2018 Jul 18.
7
[Primary ciliary dyskinesia in situs inversus without bronchiectasis].[无支气管扩张的内脏反位原发性纤毛运动障碍]
Pneumologie. 1997 Dec;51(12):1127-32.
8
A process of years: coming to terms with primary ciliary dyskinesia.多年的历程：逐渐接受原发性纤毛运动障碍
Breathe (Sheff). 2020 Jun;16(2):200116. doi: 10.1183/20734735.0116-2020.
9
Mannose-binding lectin 2 gene polymorphism and lung damage in primary ciliary dyskinesia.甘露糖结合凝集素2基因多态性与原发性纤毛运动障碍中的肺损伤
Pediatr Pulmonol. 2015 Feb;50(2):179-86. doi: 10.1002/ppul.23026. Epub 2014 Apr 19.
10
Diagnosis and management of primary ciliary dyskinesia.原发性纤毛运动障碍的诊断与管理
Cilia. 2015 Jan 22;4(1):2. doi: 10.1186/s13630-014-0011-8. eCollection 2015.
引用本文的文献
1
Rhinosinusitis: Evidence and experience - 2024.鼻窦炎：证据与经验 - 2024年
Braz J Otorhinolaryngol. 2025 May 19;91(5):101595. doi: 10.1016/j.bjorl.2025.101595.
2
Current and Future Treatments in Primary Ciliary Dyskinesia.原发性纤毛运动障碍的当前和未来治疗方法。
Int J Mol Sci. 2021 Sep 11;22(18):9834. doi: 10.3390/ijms22189834.
本文引用的文献
1
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.阿奇霉素维持疗法治疗原发性纤毛运动障碍（BESTCILIA）的疗效和安全性：一项多中心、双盲、随机、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2020 May;8(5):493-505. doi: 10.1016/S2213-2600(20)30058-8.
2
Azithromycin for primary ciliary dyskinesia: a milestone.阿奇霉素用于原发性纤毛运动障碍：一个里程碑。
Lancet Respir Med. 2020 May;8(5):429-430. doi: 10.1016/S2213-2600(20)30100-4.
3
A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.欧亚12国罕见病政策与孤儿药报销体系综述
Front Public Health. 2020 Jan 28;7:416. doi: 10.3389/fpubh.2019.00416. eCollection 2019.
4
Primary ciliary dyskinesia in the genomics age.原发性纤毛运动障碍的基因组时代。
Lancet Respir Med. 2020 Feb;8(2):202-216. doi: 10.1016/S2213-2600(19)30374-1. Epub 2019 Oct 14.
5
The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry.与α-1抗胰蛋白酶缺乏症、常见变异型免疫缺陷和原发性纤毛运动障碍相关的支气管扩张症的临床特征——来自美国支气管扩张症研究注册中心的结果
Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):145-153. doi: 10.15326/jcopdf.6.2.2018.0156.
6
The burden of rare diseases.罕见病的负担。
Am J Med Genet A. 2019 Jun;179(6):885-892. doi: 10.1002/ajmg.a.61124. Epub 2019 Mar 18.
7
Dornase alfa for cystic fibrosis.用于囊性纤维化的重组人脱氧核糖核酸酶
Cochrane Database Syst Rev. 2018 Sep 6;9(9):CD001127. doi: 10.1002/14651858.CD001127.pub4.
8
Lung function in patients with primary ciliary dyskinesia: an iPCD Cohort study.原发性纤毛运动障碍患者的肺功能：iPCD 队列研究。
Eur Respir J. 2018 Aug 23;52(2). doi: 10.1183/13993003.01040-2018. Print 2018 Aug.
9
Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers.不同欧洲中心治疗原发性纤毛运动障碍中铜绿假单胞菌根除策略的差异。
Chron Respir Dis. 2019 Jan-Dec;16:1479972318787919. doi: 10.1177/1479972318787919. Epub 2018 Jul 18.
10
Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.原发性纤毛运动障碍伴急性呼吸加重患儿的延长间隔妥布霉素药代动力学
J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):159-163. doi: 10.5863/1551-6776-23.2.159.
Zotero 插件